<DOC>
	<DOCNO>NCT00417807</DOCNO>
	<brief_summary>An open-label , non-comparative study conduct investigate activity safety imatinib mesylate refractory desmoplastic small round cell tumor express PDGF-R . Patients treat 12 month , disease progression . Tumor evaluate accord Recist criterion</brief_summary>
	<brief_title>Imatinib Mesylate Patients With Refractory Desmoplastic Small Round Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients &gt; 16 year age . 2 . Histologically documented diagnosis DSRCT , unresponsive complete remission conventional multimodality approach . 3 . Immunohistochemical documentation activate PDGFR expression tumor 4 . At least one measurable site disease 5 . Performance status 0,1 , 2 3 ( Eastern Cooperative Oncology Group ) 6 . Adequate end organ function Exclusion criterion : 1 . Patient receive investigational agent within 28 day first day study drug dosing , unless disease rapidly progress . 2 . Patient &lt; 5 year free another primary malignancy 3 . Patient congestive heart failure myocardial infarction within 6 month study 4 . Female patient pregnant breastfeeding . 5 . Severe and/or uncontrolled medical disease 6 . Known brain metastasis . 7 . Chronic active hepatitis cirrhosis 8 . Known diagnosis human immunodeficiency virus ( HIV ) infection . 9 . Chemotherapy within 4 week prior study entry , unless disease rapidly progress . 10 . Previous radiotherapy &gt; 25 % bone marrow 11 . Major surgery within 2 week prior study entry . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>refractory desmoplastic small round cell tumor</keyword>
	<keyword>PDGF-R</keyword>
</DOC>